Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results

Lung Cancer

Volumn 34, Issue SUPPL. 4, 2001, Pages 95-101

  Klastersky, J ^a   Paesmans, M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Advanced non small cell lung cancer; Chemotherapy; Objective response; QoL; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DRUG EFFICACY; DYSPNEA; HUMAN; LUNG NON SMALL CELL CANCER; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SLEEP DISORDER;

EID: 0035195364     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00383-X     Document Type: Conference Paper

References (28)

1. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
2. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis
3. Chemotherapy vs supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature
4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
5. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer
6. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy
7. Response to cytostatic treatment in inoperable adenocarcinoma of the lung: critical implications
8. Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party
9. Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC): review of the Southwest Oncology Group (SWOG) database
10. On the relationship between response to treatment and survival time
11. A quality of life instrument for use in international clinical trials in oncology
12. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life questionnaire (QLQ-C30) for use in lung cancer clinical trials
13. Measuring the quality of life of cancer patients. Functional Living Index-Cancer: development and validation
14. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist
15. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptoms Scale (LCSS)
16. Assessing the quality of life of patients in cancer clinical trials: common problems and common sense solutions
17. A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931
18. Quality of life assessment in clinical cancer research
19. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy
20. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial
21. Mitomycin, ifosfamide and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life
22. Effects of Vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer
23. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy
24. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small-cell lung cancer-a randomized trial with quality of life as the primary outcome
25. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer